Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

ting and financial planning.  These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP. Further, our reconciliations of GAAP to "adjusted" operating results, which are included on the attached tables, are presented in the format of condensed consolidated statements of income solely to facilitate a reader's understanding of the impact of the various adjustments to our GAAP operating results, individually and in the aggregate, and are not intended to place any undue prominence on our adjusted operating results.

Forward-Looking StatementsThis news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2009, and in our periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.  

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  The Company’s results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends t
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Drug safety remains front and center for the U.S. ... improve the public,s perception of the organization. Likewise, the ... consumers and recognizes that its diligence in the reporting ... effort. One issue that is impacting both ...
... 28, 2011 VirtualScopics, Inc. (Nasdaq: VSCP ), ... announced that before the market opens on Thursday, February 24, ... 2010 financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief Business ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... ... ... ... ...
... ... ... ... ...
... compared traditional surgery with less-invasive stenting to clear dangerously ... "seminal and robust." The Carotid Revascularization Endarterectomy vs. ... of both procedures are roughly equal. The trial, conducted ... the largest randomized stroke prevention trials ever. Loyola ...
... ... Conducts Statewide Outreach Efforts to Provide Low-Income Children Access to Dental Care ... ... Month draws to a close, California’s dental hygienists are reminding parents and ...
... 12,000 years ago, researchers say, , FRIDAY, Feb. 26 (HealthDay ... East more than 12,000 years ago, new research suggests. , ... IGF1 is a major determinant of small size in dogs. ... domestication of the Middle Eastern gray wolf, according to the ...
... evidence that newcomers hold mettle against warfarin, aspirin , ... more proof that the mainstays of anti-clotting therapy, namely ... newcomers. , Researchers presenting their findings during a ... meeting in San Antonio show that one new drug, ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
... of infrared laser photocoagulators includes the OcuLight ... lasers serve as a single laser source ... no regular maintenance or special electrical/cooling, and ... The OcuLight SLx is now available with ...
The simplest, most accurate Ortho-K lens fitting system ever!...
... permeable contact lenses used for corneal refractive ... (myopia). The patient wears the lenses overnight ... During the day, nearsightedness is corrected or ... RG contact lenses apply slight pressure to ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
Medicine Products: